E. Sbar

发表

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

G. Nicholas, A. Gupta, L. Chow, 2013, Cancer Chemotherapy and Pharmacology.

Phase I Study of Sequential Administration of Topotecan and 5-Fluorouracil in Patients with Advanced Malignancies

G. Grana, J. Goldberg, Jamil Khatri, 2002, Cancer investigation.

Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.

Ying Cheng, T. Mok, R. Rosell, 2018 .

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.

T. Mok, Yi-long Wu, K. Nakagawa, 2019, Future oncology.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017, The Lancet. Oncology.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

G. Giaccone, M. Socinski, M. Ahn, 2017, Lung cancer.

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Xiangdong Zhou, Maria Rita Migliorino, Kazuhiko Nakagawa, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

P. Jänne, K. O'Byrne, T. Mok, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

P. Jänne, K. O'Byrne, T. Mok, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS

S. Tantravahi, K. Chamoun, A. Kishtagari, 2022, HemaSphere.

Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.

J. Witjes, M. Galsky, H. Nishiyama, 2021, Future oncology.

KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

E. Plimack, J. Witjes, M. Galsky, 2021 .

D. Bajorin, H. Nishiyama, A. Balar, 2019, Annals of Oncology.

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017 .

Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.

M. Lacouture, A. Jatoi, S. Sonis, 2015 .

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

M. Lacouture, Dong-Wan Kim, B. Cho, 2017, Lung cancer.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017, The Lancet. Oncology.

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

M. Lacouture, A. Jatoi, S. Sonis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.